Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + melphalan + prednisone vs bortezomib + melphalan + prednisone in transplant-ineligible newly diagnosed multiple myeloma
jRCT2080222473Phase 3
- Sponsor
- Amgen
- Start
- Apr 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by Amgen.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222473.